ArticleEuropean journal of nuclear medicine and molecular imaging2026
Omitted staging PSMA PET/CT is associated with advance disease extent at time of PSA persistence: a single center retrospective analysis.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPSMA PET has emerged as a crucial imaging modality for staging intermediate- and high-risk prostate cancer (PCa), yet its implementation varies globally. This study aims to assess the diagnostic consequence of omitting pre-operative PSMA PET/CT staging by comparing the radiological features and extent of disease in two cohorts of patients who subsequently developed PSA persistence (> 0.1 ng/mL) following radical prostatectomy (RP). MATERIALS AND
methodsSingle-center, retrospective study (October 2019 to May 2025). The patient cohort included individuals who underwent radical prostatectomy and subsequently experienced PSA persistence, defined as a PSA value ≥ 0.1 ng/ml at the first measurement after 4–8 weeks after RP. Patients were divided into two groups: a Staging Cohort who underwent a pre-operative [68Ga]Ga-PSMA-11 PET/CT and a Non-Staging Cohort who did not. All patients received a [68Ga]Ga-PSMA-11PET/CT scan for PSA persistence. Clinical data, including PSA, TNM stage, and ISUP grade, as well as follow-up data were collected. The primary endpoints were the comparison of the overall PSMA PET positivity rate and the extent of both locoregional (N) and distant metastatic (M1) disease between the two cohorts. Secondary analysis included a comparison of baseline pathological characteristics and the evaluation of the potential for a theoretical change in initial patient management.
results147 patients with PSA persistence after RP were included and divided into the Staging Cohort (n = 72, 49%) and a Non-Staging Cohort (n = 75, 51%). Baseline data showed the Staging Cohort had a higher proportion of high-grade (ISUP 4/5:72% vs. 45%; p < 0.05 ) and locally advanced (T3/T4: 78% vs. 61%; p < 0.05) disease. The Non-Staging Cohort had a higher rate of positive [68Ga]Ga-PSMA-11 PET/CT scans for persistence (59%) compared to the Staging-Cohort (42%). The Non-Staging Cohort showed a markedly greater extent of disease, with a high proportion of patients (n = 34/75,45%) demonstrating findings consistent with M1 disease (bone or distant lymph nodes). The anatomical distribution of positive lymph node sites also differed: the Staging Cohort showed higher obturator nodes involvement (48% of positive sites), while the Non-Staging Cohort had a significantly higher proportion in common iliac (34%) and external/internal iliac sites. A retrospective evaluation of the Non-Staging Cohort suggested that a pre-operative [68Ga]Ga-PSMA-11 PET/CT would have triggered a theoretical change of management in all 44 positive cases, primarily by suggesting systemic therapy instead of RP for M1 patients.
conclusionThe omission of pre-operative [68Ga]Ga-PSMA-11 PET/CT is associated with a significantly higher incidence of PSMA-positive and extensive disease (locoregional and metastatic) at the time of PSA persistence. This suggests a critical diagnostic gap and potential under-staging in the Non-Staging Cohort, underscoring the vital role of early PSMA PET/CT utilization to optimize initial risk stratification and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.